PT  - JOURNAL ARTICLE
AU  - Liu, Junxi
AU  - Richmond, Rebecca C
AU  - Bowden, Jack
AU  - Barry, Ciarrah
AU  - Dashti, Hassan S
AU  - Daghlas, Iyas
AU  - Lane, Jacqueline M
AU  - Jones, Samuel E
AU  - Wood, Andrew R
AU  - Frayling, Timothy M
AU  - Wright, Alison K
AU  - Carr, Matthew J
AU  - Anderson, Simon G
AU  - Emsley, Richard
AU  - Ray, David
AU  - Weedon, Michael N
AU  - Saxena, Richa
AU  - Lawlor, Deborah A
AU  - Rutter, Martin K
TI  - Assessing the causal role of sleep traits on glycated haemoglobin: a Mendelian randomization study
AID  - 10.1101/2020.12.18.20224733
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.12.18.20224733
4099  - http://medrxiv.org/content/early/2021/01/06/2020.12.18.20224733.short
4100  - http://medrxiv.org/content/early/2021/01/06/2020.12.18.20224733.full
AB  - Objective To examine the effects of sleep traits on glycated haemoglobin (HbA1c).Design Observational multivariable regression (MVR), one-sample Mendelian randomization (1SMR), and two-sample summary data Mendelian randomization (2SMR).Setting UK Biobank (UKB) prospective cohort study and genome-wide association studies from the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC).Participants In MVR and 1SMR, participants were adults (mean (SD) age 57 (8) years; 54% female) from the UKB (n=336,999); in 2SMR, participants were adults (53 (11) years; 52% female) from MAGIC (n=46,368). All participants were adults of European ancestry.Exposures Self-reported insomnia frequency (usually vs sometimes or rarely/never); sleep duration: 24-hour sleep duration (hours/day); short sleep (≤6 hours vs 7-8 hours) and long sleep (≥9 hours vs 7-8 hours); daytime sleepiness and daytime napping (each consisting of 3 categories: never/rarely, sometimes, usually); chronotype (5 categories from definite morning to definite evening preference).Main outcome measure HbA1c in standard deviation (SD) units.Results Across MV, 1SMR, 2SMR, and their sensitivity analyses we found a higher frequency of insomnia (usually vs sometimes or rarely/never) was associated with higher HbA1c (MVR: 0.053 SD units, 95% confidence interval (0.046 to 0.061), 1SMR: 0.52, (0.42 to 0.63), 2SMR: 0.22, (0.10 to 0.35)). Results remained significant but point estimates were somewhat attenuated after excluding people with diagnosed diabetes. For other sleep traits, there was less consistency with significant associations when using some, but not all methods.Conclusions This study suggests that insomnia increases HbA1c levels. These findings could have important implications for developing and evaluating strategies that improve sleep habits to reduce hyperglycaemia and prevent diabetes.What is already known on this topicIn observational data, insomnia, short sleep duration, and evening preference are associated with higher risk for type 2 diabetes.Mendelian randomization (MR) studies have not found evidence of a causal effect of short sleep on type 2 diabetes or glycaemic traits but have indicated an effect of insomnia on type 2 diabetes. It is unclear whether insomnia influences HbA1c levels, a marker of long-term hyperglycaemia, in the general population.Recently identified genetic variants robustly associated with insomnia, sleep duration, daytime sleepiness, napping, and chronotype can be used in MR studies to explore causal effects of these sleep traits on HbA1c levels.What this study addsThis study suggests that a higher frequency of insomnia increases HbA1c levels in the general population and after excluding people with diabetes.We found no robust evidence for causal effects of other sleep traits on HbA1c levels.These findings improve our understanding of the impact of sleep traits on HbA1c levels and have important implications for developing and evaluating strategies that improve sleep habits to reduce hyperglycaemia and prevent diabetes.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.iemje.org/coi_disclosure.pdf and declare: MKR reports receiving research funding from Novo Nordisk, consultancy fees from Novo Nordisk and Roche Diabetes Care, and modest owning of shares in GlaxoSmithKline all unrelated to this work. JB reports receiving consultancy fees from Novartis unrelated to this work. DAL has received support from Roche Diagnostics and Medtronic Ltd for research unrelated to that presented here. No support from any organisation that might have an interest in the submitted work in the previous three years; no financial relationships with any organisation that might have an interest in the submitted work in the previous three year; no other relationship or activities that could appear to have influenced the submitted work.Funding StatementThis work is supported by a Diabetes UK grant (17/0005700), which funds JL, AW and SJ s salary. JL, RCR and DAL work in a unit that is funded by the University of Bristol and the UK Medical Research Council (MC_UU_00011/1 and MC_UU_00011/6) and DAL s contribution to this paper was support by a grant from the British Heart Foundation (AA/18/7/34219). DAL is a NIHR Senior Investigator (NF-0616-10102). RCR is a de Pass Vice Chancellor s research fellow at the University of Bristol. HSD and RS are funded by the National Institute of Health ((R01DK107859). RS is funded by the National Institute of Health (R01DK105072). RS is awarded the Phyllis and Jerome Lyle Rappaport Massachusetts General Hospital Research Scholar Award. JB is funded by an Establishing Excellence in England (E3) grant awarded to the University of Exeter. DWR MRC programme grant MR/P023576/1. DWR is a Wellcome Investigator, Wellcome Trust (107849/Z/15/Z, 107849/A/15/Z). CB is supported by the Wellcome Trust via a PhD [218495/Z/19/Z].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank has received ethical approval from the UK National Health Service s National Research Ethics Service (ref 11/ NW/0382).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesR scripts for the MVR, 1SMR, 2SMR, and other relevant sensitivity analyses are available on GitHub at: https://github.com/jamesliu0501/sleeptraits_glyacemic_MRproject.git. For statistical code relating to the individual level data analysis in UK Biobank, please contact the corresponding author via ieu_james.liu@bristol.ac.uk https://github.com/jamesliu0501/sleeptraits_glyacemic_MRproject.git